These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 3967582)

  • 1. Testosterone undecanoate--oral therapy for male hypogonadism.
    Drug Ther Bull; 1985 Jan; 23(2):7-8. PubMed ID: 3967582
    [No Abstract]   [Full Text] [Related]  

  • 2. A ten-year safety study of the oral androgen testosterone undecanoate.
    Gooren LJ
    J Androl; 1994; 15(3):212-5. PubMed ID: 7928661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Testosterone undecanoate for late -onset hypogonadism: an update].
    Fan XB; Huang YF
    Zhonghua Nan Ke Xue; 2010 Jan; 16(1):68-71. PubMed ID: 20180410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of the effect of methyltestosterone and testosterone undecanoate in substitution therapy of hypogonadism].
    Hána V; Marek J; Mellanová A; Hampl R; Stárka L
    Cas Lek Cesk; 1987 Mar; 126(12):369-73. PubMed ID: 3555827
    [No Abstract]   [Full Text] [Related]  

  • 5. Oral testosterone undecanoate (Andriol) supplement therapy improves the quality of life for men with testosterone deficiency.
    Park NC; Yan BQ; Chung JM; Lee KM
    Aging Male; 2003 Jun; 6(2):86-93. PubMed ID: 12898792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of testosterone undecanoate in male hypogonadism.
    Maisey NM; Bingham J; Marks V; English J; Chakraborty J
    Clin Endocrinol (Oxf); 1981 Jun; 14(6):625-9. PubMed ID: 7296909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical study.
    Morgentaler A; Dobs AS; Kaufman JM; Miner MM; Shabsigh R; Swerdloff RS; Wang C
    J Urol; 2008 Dec; 180(6):2307-13. PubMed ID: 18930255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral testosterone replacement in Korean patients with PADAM.
    Hong JH; Ahn TY
    Aging Male; 2002 Mar; 5(1):52-6. PubMed ID: 12040976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma levels of dihydrotestosterone remain in the normal range in men treated with long-acting parenteral testosterone undecanoate.
    Yassin AA; Saad F
    Andrologia; 2007 Oct; 39(5):181-4. PubMed ID: 17714216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new oral testosterone undecanoate formulation.
    Köhn FM; Schill WB
    World J Urol; 2003 Nov; 21(5):311-5. PubMed ID: 14579074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen replacement therapy.
    Osterman J
    Curr Ther Endocrinol Metab; 1994; 5():286-91. PubMed ID: 7704734
    [No Abstract]   [Full Text] [Related]  

  • 12. 54-year-old man with breast cancer after prolonged testosterone therapy.
    Sorscher S; Krause W
    Clin Adv Hematol Oncol; 2005 Jun; 3(6):475; discussion 476. PubMed ID: 16167025
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effect of testosterone undeconoate in male hypogonadism].
    Mies R; Krempl S
    Med Welt; 1980 Apr; 31(17):619-21. PubMed ID: 7421495
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of a Novel Oral Testosterone Undecanoate on Ambulatory Blood Pressure in Hypogonadal Men.
    White WB; Dobs A; Carson C; DelConte A; Khera M; Miner M; Shahid M; Kim K; Chidambaram N
    J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):630-637. PubMed ID: 34191621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pubertal induction in adult males with isolated hypogonadotropic hypogonadism using long-acting intramuscular testosterone undecanoate 1-g depot (Nebido).
    Santhakumar A; Miller M; Quinton R
    Clin Endocrinol (Oxf); 2014 Jan; 80(1):155-7. PubMed ID: 23383861
    [No Abstract]   [Full Text] [Related]  

  • 16. Testosterone Undecanoate-Schering AG.
    Drugs R D; 2004; 5(6):368-9. PubMed ID: 15563244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer?
    Gould DC; Kirby RS
    Prostate Cancer Prostatic Dis; 2006; 9(1):14-8. PubMed ID: 16264770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with Andriol Testocaps--the first Austrian surveillance study on the treatment of late-onset hypogonadism.
    Jungwirth A; Plas E; Geurts P
    Aging Male; 2007 Dec; 10(4):183-7. PubMed ID: 18033627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Xyosted--a testosterone auto-injector for hypogonadism.
    Med Lett Drugs Ther; 2019 Mar; 61(1567):37-38. PubMed ID: 30845097
    [No Abstract]   [Full Text] [Related]  

  • 20. Sustained anabolic effects of long-term androgen administration in men with AIDS wasting.
    Grinspoon S; Corcoran C; Anderson E; Hubbard J; Stanley T; Basgoz N; Klibanski A
    Clin Infect Dis; 1999 Mar; 28(3):634-6. PubMed ID: 10194091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.